{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:14:32Z","timestamp":1773281672507,"version":"3.50.1"},"reference-count":127,"publisher":"Bentham Science Publishers Ltd.","issue":"9","funder":[{"DOI":"10.13039\/501100000780","name":"European Commission Programme","doi-asserted-by":"publisher","award":["4246"],"award-info":[{"award-number":["4246"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2019,6,11]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Advanced age-related macular degeneration (AMD) is the leading cause of blindness in the elderly with limited therapeutic options. The disease is characterized by photoreceptor loss in the macula and reduced Retinal Pigment Epithelium (RPE) function, associated with matrix degradation, cell proliferation, neovascularization and inflammation. Matrix metalloproteinases (MMPs), a disintegrin and metalloproteinases (ADAMs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTSs) play a critical role in the physiology of extracellular matrix (ECM) turnover and, in turn, in ECM pathologies, such as AMD. A balance between the activities of MMPs and Tissue Inhibitors of Metalloproteinase (TIMPs) is crucial for the integrity of the ECM components; indeed, a dysregulation in the ratio of these factors produces profound changes in the ECM, including thickening and deposit formation, which eventually might lead to AMD development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>This article reviews the relevance and impact of zinc metalloproteinases on the development of AMD and their roles as biomarkers and\/or therapeutic targets. We illustrate some studies on several inhibitors of MMPs currently used to dissect physiological properties of MMPs. Moreover, all molecules or technologies used to control MMP and ADAM activity in AMD are analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>This study underlines the changes in the activity of MMPs expressed by RPE cells, highlights the functions of already used MMP inhibitors and consequently suggests their application as therapeutic agents for the treatment of AMD.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389450120666190122114857","type":"journal-article","created":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T11:54:00Z","timestamp":1548158040000},"page":"903-918","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Age-related Macular Degeneration: Current Knowledge of Zinc Metalloproteinases Involvement"],"prefix":"10.2174","volume":"20","author":[{"given":"Francesca","family":"Liva","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doretta","family":"Cuffaro","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Nuti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Nencetti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Orlandini","sequence":"additional","affiliation":[{"name":"Research Center , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Vozzi","sequence":"additional","affiliation":[{"name":"Research Center , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Rossello","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.exer.2005.04.012","volume":"81","author":"Curcio C.A.","year":"2005","unstructured":"Curcio CA, Presley JB, Malek G, Medeiros NE, Avery DV, Kruth HS. Esterified and unesterified cholesterol in drusen and basal deposits of eyes with age-related maculopathy.","journal-title":"Exp Eye Res"},{"key":"ref=2","first-page":"64","volume":"76","author":"Hogan M.J.","year":"1972","unstructured":"Hogan MJ. Role of the retinal pigment epithelium in macular disease.","journal-title":"Trans Am Acad Ophthalmol Otolaryngol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/nrc2459","volume":"8","author":"Murphy G.","year":"2008","unstructured":"Murphy G. The ADAMs: signalling scissors in the tumour microenvironment.","journal-title":"Nat Rev Cancer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"Jager R.D.","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW. Age-related macular degeneration.","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"Lim L.S.","year":"2012","unstructured":"Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration.","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/ng.3448","volume":"48","author":"Fritsche L.G.","year":"2016","unstructured":"Fritsche LG, Igl W, Bailey JN. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.","journal-title":"Nat Genet"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/oxfordjournals.aje.a117648","volume":"142","author":"Vingerling J.R.","year":"1995","unstructured":"Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study.","journal-title":"Am J Epidemiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1001\/jama.1994.03520180037032","volume":"272","author":"Seddon J.M.","year":"1994","unstructured":"Seddon JM, Ajani UA, Sperduto RD. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration.","journal-title":"JAMA"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archopht.1941.00870100042005","volume":"122","author":"Friedman D.S.","year":"2004","unstructured":"Friedman DS, O\u2019Colmain BJ, Mu\u00f1oz B. Prevalence of age-related macular degeneration in the United States.","journal-title":"Arch Ophthalmol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1167\/iovs.07-1584","volume":"49","author":"Chang M.A.","year":"2008","unstructured":"Chang MA, Bressler SB, Munoz B, West SK. Racial differences and other risk factors for incidence and progression of age-related macular degeneration: Salisbury Eye Evaluation (SEE) Project.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1590\/S0004-27492013000 200005","volume":"76","author":"Nano M.E.","year":"2013","unstructured":"Nano ME, Lansingh VC, Pighin MS. Risk factors of age-related macular degeneration in Argentina.","journal-title":"Arq Bras Oftalmol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/archopht.119.10.1455","volume":"119","author":"McCarty C.A.","year":"2001","unstructured":"McCarty CA, Mukesh BN, Fu CL, Mitchell P, Wang JJ, Taylor HR. Risk factors for age-related maculopathy: the Visual Impairment Project.","journal-title":"Arch Ophthalmol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"E4472","DOI":"10.1073\/pnas.1702302114","volume":"114","author":"Rowan S.","year":"2017","unstructured":"Rowan S, Jiang S, Korem T. Involvement of a gut-retina axis in protection against dietary glycemia-induced age-related macular degeneration.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=14","first-page":"171","volume":"10","author":"Armstrong R.A.","year":"2015","unstructured":"Armstrong RA, Mousavi M. Overview of risk factors for Age-Related Macular Degeneration (AMD).","journal-title":"J Stem Cells"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"c981","DOI":"10.1136\/bmj.c981","volume":"340","author":"Chakravarthy U.","year":"2010","unstructured":"Chakravarthy U, Evans J, Rosenfeld PJ. Age related macular degeneration.","journal-title":"BMJ"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1006\/exer.2001.1094","volume":"73","author":"Johnson L.V.","year":"2001","unstructured":"Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration.","journal-title":"Exp Eye Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1126\/science.1110189","volume":"308","author":"Edwards A.O.","year":"2005","unstructured":"Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration.","journal-title":"Science"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/ng1750","volume":"38","author":"Gold B.","year":"2006","unstructured":"Gold B, Merriam JE, Zernant J. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.","journal-title":"Nat Genet"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"Jager R.D.","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW. Age-related macular degeneration.","journal-title":"N Engl J Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.3389\/fimmu.2018.00808","volume":"9","author":"Molins B.","year":"2018","unstructured":"Molins B, Romero-V\u00e1zquez S, Fuentes-Prior P, Adan A, Dick AD. C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration.","journal-title":"Front Immunol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.12659\/MSM.889887","volume":"20","author":"Nita M.","year":"2014","unstructured":"Nita M, Strza\u0142ka-Mrozik B, Grzybowski A, Mazurek U, Romaniuk W. Age-related macular degeneration and changes in the extracellular matrix.","journal-title":"Med Sci Monit"},{"key":"ref=22","first-page":"1156","volume":"22","author":"Kutty R.K.","year":"2016","unstructured":"Kutty RK, Samuel W, Boyce K. Proinflammatory cytokines decrease the expression of genes critical for RPE function.","journal-title":"Mol Vis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1001\/archopht.123.11.1570","volume":"123","author":"Ferris F.L.","year":"2005","unstructured":"Ferris FL, Davis MD, Clemons TE. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18.","journal-title":"Arch Ophthalmol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13) 70145-1","volume":"2","author":"Wong W.L.","year":"2014","unstructured":"Wong WL, Su X, Li X. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.","journal-title":"Lancet Glob Health"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/archopht.119.10.1417","volume":"119","author":"","year":"2001","unstructured":". A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.","journal-title":"Arch Ophthalmol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1001\/jama.288.18.2358","volume":"288","author":"Parmet S.","year":"2002","unstructured":"Parmet S, Lynm C, Glass RM. JAMA patient page. Age-related macular degeneration.","journal-title":"JAMA"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2147\/CIA.S143508","volume":"12","author":"Al-Zamil W.M.","year":"2017","unstructured":"Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review.","journal-title":"Clin Interv Aging"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s12325-018-0698-9","volume":"35","author":"Bennett N.","year":"2018","unstructured":"Bennett N, John L, Likhar N, Agrawal R, Amoaku WM. Clinical Efficacy and Safety of Current Interventions for Choroidal Neovascularization Associated with Rare Diseases: A Systematic Literature Review.","journal-title":"Adv Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1146\/annurev-genom-090413-025610","volume":"15","author":"Fritsche L.G.","year":"2014","unstructured":"Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. Age-related macular degeneration: genetics and biology coming together.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0002-9440(10)62248-1","volume":"166","author":"Chong N.H.","year":"2005","unstructured":"Chong NH, Keonin J, Luthert PJ. Decreased thickness and integrity of the macular elastic layer of Bruch\u2019s membrane correspond to the distribution of lesions associated with age-related macular degeneration.","journal-title":"Am J Pathol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"18751","DOI":"10.1073\/pnas.090501 0106","volume":"106","author":"Saint-Geniez M.","year":"2009","unstructured":"Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D\u2019Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=32","unstructured":"Bruch\u2019s Membrane: The Critical Boundaryin Macular Degeneration. In: Ying GS, ed. Age Related MacularDegeneration. Rec Adv Basic Res Clin Care 2012; 3: 300."},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.12659\/MSM.889887","volume":"20","author":"Nita M.","year":"2014","unstructured":"Nita M, Strza\u0142ka-Mrozik B, Grzybowski A, Mazurek U, Romaniuk W. Age-related macular degeneration and changes in the extracellular matrix.","journal-title":"Med Sci Monit"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"802","DOI":"10.2174\/156652410793937813","volume":"10","author":"Sparrow J.R.","year":"2010","unstructured":"Sparrow JR, Hicks D, Hamel CP. The retinal pigment epithelium in health and disease.","journal-title":"Curr Mol Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.exer. 2009.06.014","volume":"89","author":"Alcazar O.","year":"2009","unstructured":"Alcazar O, Cousins SW, Striker GE, Marin-Castano ME. (Pro)renin receptor is expressed in human retinal pigment epithelium and participates in extracellular matrix remodeling.","journal-title":"Exp Eye Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bbamcr.2010.01.003","volume":"1803","author":"Brew K.","year":"2010","unstructured":"Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.","journal-title":"Biochim Biophys Acta"},{"key":"ref=37","first-page":"2520","volume":"31","author":"Alexander J.P.","year":"1990","unstructured":"Alexander JP, Bradley JM, Gabourel JD, Acott TS. Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=38","first-page":"1049","volume":"9","author":"Rhoades W.","year":"2015","unstructured":"Rhoades W, Dickson D, Do DV. Potential role of lampalizumab for treatment of geographic atrophy.","journal-title":"Clin Ophthalmol"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"ahttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT022474792017.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02247531bHolz FG, Sadda SR, BusbeeB, et al. Efficacy and safety of lampalizumab for geographic atrophydue to age-related macular degeneration: Chroma and spectri phase 3randomized clinical trials. JAMA Ophthalmol 2018; 136(6): 666-77.","DOI":"10.1001\/jamaophthalmol.2018.1544"},{"key":"ref=40","unstructured":"Clinical study to evaluate treatment with Oracea\u00ae for geo-graphicatrophy (TOGA). NLM identifier: NCT01782989 [Accessed on December 17,2018.];"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/clpt.2014.174","volume":"96","author":"Szeto H.H.","year":"2014","unstructured":"Szeto HH, Birk AV. Serendipity and the discovery of novel compounds that restore mitochondrial plasticity.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=42","unstructured":"A study of MTP-131 topical ophthalmic solution in subjects withdiabetic macular edema and non-exudative intermediate age-relatedmacular degeneration (SPIOC-101). identifier: NCT02314299 [Accessedon December 17, 2018.];"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"Gragoudas E.S.","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration.","journal-title":"N Engl J Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/jcm4020343","volume":"4","author":"Yonekawa Y.","year":"2015","unstructured":"Yonekawa Y, Miller JW, Kim IK. Age-related macular degeneration: advances in management and diagnosis.","journal-title":"J Clin Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1157","DOI":"10. 1136\/bjophthalmol-2011-300654","volume":"96","author":"Stewart M.W.","year":"2012","unstructured":"Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug.","journal-title":"Br J Ophthalmol"},{"key":"ref=46","unstructured":"A phase 1, safety, tolerability and pharmacokinetic profile of intravitreousinjections of E10030 (anti-PDGF pegylated ap-tamer) insubjects with neovascular age-related macular de-generation. NLM identifier:NCT00569140 [Accessed on December 17, 2018.];"},{"key":"ref=47","unstructured":"A safety and efficacy study of E10030 (antiPDGF pegylated aptamer)plus lucentis for neovascular age-related macular degeneration. identifier: NCT01089517 [Accessed on December 17, 2018.];"},{"key":"ref=48","first-page":"1308","volume":"10","author":"Singh M.","year":"2017","unstructured":"Singh M, Tyagi SC. Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology.","journal-title":"Int J Ophthalmol"},{"key":"ref=49","first-page":"2676","volume":"40","author":"Guo L.","year":"1999","unstructured":"Guo L, Hussain AA, Limb GA, Marshall J. Age-dependent variation in metalloproteinase activity of isolated human Bruch\u2019s membrane and choroid.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=50","first-page":"S973","volume":"40","author":"Hussain A.A.","year":"1999","unstructured":"Hussain AA, Starita C, Marshall J. Molecular weight size exclusion limit and diffusional status of aging human Bruch\u2019s membrane.","journal-title":"IOVS"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.6001\/biologija.v60i2.2910","volume":"60","author":"Liutkeviciene R.","year":"2014","unstructured":"Liutkeviciene R, Sinkunaite-Marsalkiene G, Asmoniene V, Zaliuniene D. An impact of mutation on MMP-2, -3 and -9 activity regulation and influence on age-related macular degeneration development: literature review.","journal-title":"Biologija (Vilnius)"},{"key":"ref=52","first-page":"2767","volume":"43","author":"Eichler W.","year":"2002","unstructured":"Eichler W, Friedrichs U, Thies A, Tratz C, Wiedemann P. Modulation of matrix metalloproteinase and TIMP-1 expression by cytokines in human RPE cells.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1006\/exer.1998.0552","volume":"67","author":"Plantner J.J.","year":"1998","unstructured":"Plantner JJ, Jiang C, Smine A. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration.","journal-title":"Exp Eye Res"},{"key":"ref=54","first-page":"2367","volume":"40","author":"Kamei M.","year":"1999","unstructured":"Kamei M, Hollyfield JG. TIMP-3 in Bruch\u2019s membrane: changes during aging and in age-related macular degeneration.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"4459","DOI":"10.1167\/iovs.10-6678","volume":"52","author":"Hussain A.A.","year":"2011","unstructured":"Hussain AA, Lee Y, Zhang JJ, Marshall J. Disturbed matrix metalloproteinase activity of Bruch\u2019s membrane in age-related macular degeneration.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1350-9462(98)00024-X","volume":"18","author":"Hiscott P.","year":"1999","unstructured":"Hiscott P, Sheridan C, Magee RM, Grierson I. Matrix and the retinal pigment epithelium in proliferative retinal disease.","journal-title":"Prog Retin Eye Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/(SICI)1097-4644(19990701)74:1<135: AID-JCB15>3.0.CO;2-#","volume":"74","author":"Mousa S.A.","year":"1999","unstructured":"Mousa SA, Lorelli W, Campochiaro PA. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells.","journal-title":"J Cell Biochem"},{"key":"ref=58","first-page":"2194","volume":"39","author":"Steen B.","year":"1998","unstructured":"Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1167\/iovs.06-1234","volume":"48","author":"Hollborn M.","year":"2007","unstructured":"Hollborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L, Bringmann A. Positive feedback regulation between MMP-9 and VEGF in human RPE cells.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=60","first-page":"3179","volume":"34","author":"Hunt R.C.","year":"1993","unstructured":"Hunt RC, Fox A, al Pakalnis V. Cytokines cause cultured retinal pigment epithelial cells to secrete metalloproteinases and to contract collagen gels.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/01.iae.0000238549.74626.33","volume":"26","author":"Hoffmann S.","year":"2006","unstructured":"Hoffmann S, He S, Ehren M, Ryan SJ, Wiedemann P, Hinton DR. MMP-2 and MMP-9 secretion by rpe is stimulated by angiogenic molecules found in choroidal neovascular membranes.","journal-title":"Retina"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/01.GIM.0000159903.69597.73","volume":"7","author":"Fiotti N.","year":"2005","unstructured":"Fiotti N, Pedio M, Battaglia Parodi M. MMP-9 microsatellite polymorphism and susceptibility to exudative form of age-related macular degeneration.","journal-title":"Genet Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3109\/13816810.2013.838274","volume":"36","author":"Liutkeviciene R.","year":"2015","unstructured":"Liutkeviciene R, Lesauskaite V, Sinkunaite-Marsalkiene G. The role of matrix metalloproteinases polymorphisms in age-related macular degeneration.","journal-title":"Ophthalmic Genet"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1167\/iovs.04-1224","volume":"46","author":"Marin-Casta\u00f1o M.E.","year":"2005","unstructured":"Marin-Casta\u00f1o ME, Csaky KG, Cousins SW. Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=65","first-page":"458","volume":"43","author":"Ahir A.","year":"2002","unstructured":"Ahir A, Guo L, Hussain AA, Marshall J. Expression of metalloproteinases from human retinal pigment epithelial cells and their effects on the hydraulic conductivity of Bruch\u2019s membrane.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1167\/iovs.05-1258","volume":"47","author":"Elliot S.","year":"2006","unstructured":"Elliot S, Catanuto P, Stetler-Stevenson W, Cousins SW. Retinal pigment epithelium protection from oxidant-mediated loss of MMP-2 activation requires both MMP-14 and TIMP-2.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=67","first-page":"3460","volume":"55","author":"Or C.","year":"2014","unstructured":"Or C, Wang J, Kojic L, Cui Z, Matsubara JA. Expression of ADAMs (A Disintegrin and Metalloproteinase) 10 and 17 in human eyes and in experimental models of age related macular degeneration (AMD).","journal-title":"IOVS"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"5162","DOI":"10.1167\/iovs.14-16058","volume":"56","author":"Park G.B.","year":"2015","unstructured":"Park GB, Kim D, Kim YS. Regulation of ADAM10 and ADAM17 by sorafenib inhibits epithelial-to-mesenchymal transition in epstein-barr virus-infected retinal pigment epithelial cells.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ejcb.2010.11.005","volume":"90","author":"Saftig P.","year":"2011","unstructured":"Saftig P, Reiss K. The \u201cA Disintegrin And Metalloproteases\u201d ADAM10 and ADAM17: novel drug targets with therapeutic potential?","journal-title":"Eur J Cell Biol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1083\/jcb.200307137","volume":"164","author":"Sahin U.","year":"2004","unstructured":"Sahin U, Weskamp G, Kelly K. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands.","journal-title":"J Cell Biol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0886-3350(01)01236-6","volume":"28","author":"Lim J.M.","year":"2002","unstructured":"Lim JM, Lee JH, Wee WR, Joo CK. Downregulated expression of ADAM9 in anterior polar cataracts.","journal-title":"J Cataract Refract Surg"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1161\/CIRCRESAHA.108.184416","volume":"103","author":"Swendeman S.","year":"2008","unstructured":"Swendeman S, Mendelson K, Weskamp G. VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling.","journal-title":"Circ Res"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1242\/dev.055210","volume":"138","author":"Weber S.","year":"2011","unstructured":"Weber S, Niessen MT, Prox J. The disintegrin\/metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling.","journal-title":"Development"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.immuni.2012.01.005","volume":"36","author":"Murthy A.","year":"2012","unstructured":"Murthy A, Shao YW, Narala SR, Molyneux SD, Z\u00fa\u00f1iga-Pfl\u00fccker JC, Khokha R. Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis.","journal-title":"Immunity"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ajhg.2009.04.005","volume":"84","author":"Parry D.A.","year":"2009","unstructured":"Parry DA, Toomes C, Bida L. Loss of the metalloprotease ADAM9 leads to cone-rod dystrophy in humans and retinal degeneration in mice.","journal-title":"Am J Hum Genet"},{"key":"ref=76","first-page":"260","volume":"43","author":"Majka S.","year":"2002","unstructured":"Majka S, McGuire PG, Das A. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=77","first-page":"4324","volume":"41","author":"Jin M.","year":"2000","unstructured":"Jin M, He S, W\u00f6rpel V, Ryan SJ, Hinton DR. Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-alpha.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0167-4781(03)00047-2","volume":"1626","author":"Bevitt D.J.","year":"2003","unstructured":"Bevitt DJ, Mohamed J, Catterall JB. Expression of ADAMTS metalloproteinases in the retinal pigment epithelium derived cell line ARPE-19: transcriptional regulation by TNFalpha.","journal-title":"Biochim Biophys Acta"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.preteyeres.2003.08.001","volume":"22","author":"Das A.","year":"2003","unstructured":"Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition.","journal-title":"Prog Retin Eye Res"},{"key":"ref=80","first-page":"2055","volume":"34","author":"Hackett S.F.","year":"1993","unstructured":"Hackett SF, Campochiaro PA. Modulation of plasminogen activator inhibitor-1 and urokinase in retinal pigmented epithelial cells.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1076\/0271-3683(200009)2131-RFT684","volume":"21","author":"Kvanta A.","year":"2000","unstructured":"Kvanta A, Shen WY, Sarman S, Seregard S, Steen B, Rakoczy E. Matrix metalloproteinase (MMP) expression in experimental choroidal neovascularization.","journal-title":"Curr Eye Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S0002-9440(10)64401-X","volume":"161","author":"Lambert V.","year":"2002","unstructured":"Lambert V, Munaut C, Jost M. Matrix metalloproteinase-9 contributes to choroidal neovascularization.","journal-title":"Am J Pathol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1096\/fj.03-0113fje","volume":"17","author":"Lambert V.","year":"2003","unstructured":"Lambert V, Wielockx B, Munaut C. MMP-2 and MMP-9 synergize in promoting choroidal neovascularization.","journal-title":"FASEB J"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/archopht.117.4.498","volume":"117","author":"Das A.","year":"1999","unstructured":"Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor.","journal-title":"Arch Ophthalmol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1167\/iovs.02-0180","volume":"44","author":"Berglin L.","year":"2003","unstructured":"Berglin L, Sarman S, van der Ploeg I. Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=86","first-page":"729","volume":"19","author":"Zeng R.","year":"2013","unstructured":"Zeng R, Wen F, Zhang X, Su Y. Serum levels of matrix metalloproteinase 2 and matrix metalloproteinase 9 elevated in polypoidal choroidal vasculopathy but not in age-related macular degeneration.","journal-title":"Mol Vis"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/sj.eye. 6702722x","volume":"22","author":"Chau K.Y.","year":"2008","unstructured":"Chau KY, Sivaprasad S, Patel N, Donaldson TA, Luthert PJ, Chong NV. Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration.","journal-title":"Eye (Lond)"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/bjo.2007.114769","volume":"91","author":"Tatar O.","year":"2007","unstructured":"Tatar O, Adam A, Shinoda K. Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.","journal-title":"Br J Ophthalmol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1097\/IAE.0b013 e3182576d07","volume":"32","author":"Jonas J.B.","year":"2012","unstructured":"Jonas JB, Jonas RA, Neumaier M, Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema.","journal-title":"Retina"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"e0159720","DOI":"10.1371\/journal.pone.0159720","volume":"11","author":"Kwon J.W.","year":"2016","unstructured":"Kwon JW, Choi JA, Jee D. Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Aqueous Humor of Diabetic Macular Edema Patients.","journal-title":"PLoS One"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1167\/iovs.02-0281","volume":"44","author":"Wang F.","year":"2003","unstructured":"Wang F, Rendahl KG, Manning WC, Quiroz D, Coyne M, Miller SS. AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","volume":"22","author":"Witmer A.N.","year":"2003","unstructured":"Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease.","journal-title":"Prog Retin Eye Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1083\/jcb.200409115","volume":"169","author":"Lee S.","year":"2005","unstructured":"Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors.","journal-title":"J Cell Biol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.semcdb. 2007.06.008","volume":"19","author":"Barbolina M.V.","year":"2008","unstructured":"Barbolina MV, Stack MSN. Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis.","journal-title":"Semin Cell Dev Biol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1091\/mbc.e06-08-0740","volume":"17","author":"Itoh Y.","year":"2006","unstructured":"Itoh Y, Ito N, Nagase H, Evans RD, Bird SA, Seiki M. Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP.","journal-title":"Mol Biol Cell"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/0929867325666180326164104","volume":"25","author":"Camodeca C.","year":"2018","unstructured":"Camodeca C, Cuffaro D, Nuti E, Rossello A. ADAM metalloproteinases as potential drug targets.","journal-title":"Curr Med Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.mam.2008.08.001","volume":"29","author":"Edwards D.R.","year":"2008","unstructured":"Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases.","journal-title":"Mol Aspects Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ceb.2003.08.001","volume":"15","author":"White J.M.","year":"2003","unstructured":"White JM. ADAMs: modulators of cell-cell and cell-matrix interactions.","journal-title":"Curr Opin Cell Biol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1440-169X.2011.01282.x","volume":"53","author":"Yan X.","year":"2011","unstructured":"Yan X, Lin J, Rolfs A, Luo J. Differential expression of the ADAMs in developing chicken retina.","journal-title":"Dev Growth Differ"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.2174\/1389450117666160727143618","volume":"17","author":"Rossello A.","year":"2016","unstructured":"Rossello A, Nuti E, Ferrini S, Fabbi M. Targeting ADAM17 Sheddase Activity in Cancer.","journal-title":"Curr Drug Targets"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/sj.jid.5701242","volume":"128","author":"Maretzky T.","year":"2008","unstructured":"Maretzky T, Scholz F, K\u00f6ten B, Proksch E, Saftig P, Reiss K. ADAM10-mediated E-cadherin release is regulated by proinflammatory cytokines and modulates keratinocyte cohesion in eczematous dermatitis.","journal-title":"J Invest Dermatol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13059-015-0676-3","volume":"16","author":"Kelwick R.","year":"2015","unstructured":"Kelwick R, Desanlis I, Wheeler GN, Edwards DR. The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family.","journal-title":"Genome Biol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1006\/exer.1999.0707","volume":"69","author":"Hollyfield J.G.","year":"1999","unstructured":"Hollyfield JG, Rayborn ME, Midura RJ, Shadrach KG, Acharya S. Chondroitin sulfate proteoglycan core proteins in the interphotoreceptor matrix: a comparative study using biochemical and immunohistochemical analysis.","journal-title":"Exp Eye Res"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1073\/pnas.94.6.2374","volume":"94","author":"Colige A.","year":"1997","unstructured":"Colige A, Li SW, Sieron AL, Nusgens BV, Prockop DJ, Lapi\u00e8re CM. cDNA cloning and expression of bovine procollagen I N-proteinase: a new member of the superfamily of zinc-metalloproteinases with binding sites for cells and other matrix components.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"31502","DOI":"10.1074\/jbc.M103466200","volume":"276","author":"Fernandes R.J.","year":"2001","unstructured":"Fernandes RJ, Hirohata S, Engle JM. Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis.","journal-title":"J Biol Chem"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00417-001-0398-y","volume":"240","author":"Wang Y.S.","year":"2002","unstructured":"Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12885-017-3418-y","volume":"17","author":"Webb A.H.","year":"2017","unstructured":"Webb AH, Gao BT, Goldsmith ZK. Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in models of retinoblastoma.","journal-title":"BMC Cancer"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/138945011794182746","volume":"12","author":"Becerra E.M.","year":"2011","unstructured":"Becerra EM, Morescalchi F, Gandolfo F. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.","journal-title":"Curr Drug Targets"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1167\/iovs.08-3174","volume":"50","author":"Samtani S.","year":"2009","unstructured":"Samtani S, Amaral J, Campos MM, Fariss RN, Becerra SP. Doxycycline-mediated inhibition of choroidal neovascularization.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.3892\/etm.2017.4110","volume":"13","author":"Kim D.","year":"2017","unstructured":"Kim D, Ko HS, Park GB, Hur DY, Kim YS, Yang JW. Vandetanib and ADAM inhibitors synergistically attenuate the pathological migration of EBV-infected retinal pigment epithelial cells by regulating the VEGF-mediated MAPK pathway.","journal-title":"Exp Ther Med"},{"key":"ref=111","first-page":"336","volume":"3","author":"Griffioen A.W.","year":"2000","unstructured":"Griffioen AW. AG-3340 (Agouron Pharmaceuticals Inc).","journal-title":"IDrugs"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1089\/1080768041223657","volume":"20","author":"El Bradey M.","year":"2004","unstructured":"El Bradey M, Cheng L, Bartsch DU. Preventive treatment effect of AG3340, a potent matrix metalloproteinase inhibitor in a rat model of choroidal neovascularization.","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00417-003-0761-2","volume":"241","author":"Kohri T.","year":"2003","unstructured":"Kohri T, Moriwaki M, Nakajima M, Tabuchi H, Shiraki K. Reduction of experimental laser-induced choroidal neovascularization by orally administered BPHA, a selective metalloproteinase inhibitor.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1001\/archopht.117.4.498","volume":"117","author":"Das A.","year":"1999","unstructured":"Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor.","journal-title":"Arch Ophthalmol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1076\/ceyr.24.1.33.5429","volume":"24","author":"Garcia C.","year":"2002","unstructured":"Garcia C, Bartsch DU, Rivero ME. Efficacy of Prinomastat) (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization.","journal-title":"Curr Eye Res"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1517\/14656566.6.10.1681","volume":"6","author":"Pasquale T.R.","year":"2005","unstructured":"Pasquale TR, Tan JS. Update on antimicrobial agents: new indications of older agents.","journal-title":"Expert Opin Pharmacother"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.ophtha.2010.01.037","volume":"117","author":"Cox C.A.","year":"2010","unstructured":"Cox CA, Amaral J, Salloum R. Doxycycline\u2019s effect on ocular angiogenesis: an analysis.","journal-title":"Ophthalmology"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00417-010-1539-y","volume":"249","author":"Su W.","year":"2011","unstructured":"Su W, Li Z, Lin M. The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"9108","DOI":"10.1167\/iovs.11-7255","volume":"52","author":"Su W.","year":"2011","unstructured":"Su W, Li Z, Li Y. Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1167\/iovs.12-10323","volume":"54","author":"Su W.","year":"2013","unstructured":"Su W, Li Z, Li F, Chen X, Wan Q, Liang D. Doxycycline-mediated inhibition of corneal angiogenesis: an MMP-independent mechanism.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1124\/mol.104.006346","volume":"67","author":"Garc\u00eda R.A.","year":"2005","unstructured":"Garc\u00eda RA, Pantazatos DP, Gessner CR, Go KV, Woods VL, Villarreal FJ. Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry.","journal-title":"Mol Pharmacol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-11-2041","volume":"18","author":"Inoue K.","year":"2012","unstructured":"Inoue K, Torimura T, Nakamura T. Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.","journal-title":"Clin Cancer Res"},{"key":"ref=123","first-page":"198","volume":"119","author":"Bressler N.M.","year":"2001","unstructured":"Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.","journal-title":"Arch Ophthalmol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0002-9394(01)00967-9","volume":"131","author":"","year":"2001","unstructured":". Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2.","journal-title":"Am J Ophthalmol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/bjo.2007.114769","volume":"91","author":"Tatar O.","year":"2007","unstructured":"Tatar O, Adam A, Shinoda K. Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.","journal-title":"Br J Ophthalmol"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/labinvest.3780060","volume":"80","author":"Zhu W.H.","year":"2000","unstructured":"Zhu WH, Guo X, Villaschi S, Francesco Nicosia R. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis.","journal-title":"Lab Invest"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1167\/iovs.11-8585","volume":"53","author":"Zhang J.J.","year":"2012","unstructured":"Zhang JJ, Sun Y, Hussain AA, Marshall J. Laser-mediated activation of human retinal pigment epithelial cells and concomitant release of matrix metalloproteinases.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T19:47:16Z","timestamp":1662839236000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169229\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":127,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,6,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450120666190122114857","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}